Fate Therapeutics Inc. (FATE)
undefined
undefined%
At close: undefined
1.84
1.10%
After-hours Dec 13, 2024, 06:15 PM EST

Fate Therapeutics Statistics

Share Statistics

Fate Therapeutics has 113.89M shares outstanding. The number of shares has increased by 15.49% in one year.

Shares Outstanding 113.89M
Shares Change (YoY) n/a
Shares Change (QoQ) 0.04%
Owned by Institutions (%) n/a
Shares Floating 97.96M
Failed to Deliver (FTD) Shares 155
FTD / Avg. Volume 0.01%

Short Selling Information

The latest short interest is 15.90M, so 13.96% of the outstanding shares have been sold short.

Short Interest 15.90M
Short % of Shares Out 13.96%
Short % of Float 16.23%
Short Ratio (days to cover) 12.76

Valuation Ratios

The PE ratio is -2.29 and the forward PE ratio is -1.42.

PE Ratio -2.29
Forward PE -1.42
PS Ratio 5.79
Forward PS 53.4
PB Ratio 1
P/FCF Ratio -2.66
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

Fate Therapeutics Inc. has an Enterprise Value (EV) of 429.72M.

EV / Earnings -2.67
EV / Sales 6.76
EV / EBITDA -2.5
EV / EBIT -2.26
EV / FCF -3.1

Financial Position

The company has a current ratio of 8.48, with a Debt / Equity ratio of 0.02.

Current Ratio 8.48
Quick Ratio 8.48
Debt / Equity 0.02
Total Debt / Capitalization 1.65
Cash Flow / Debt -21.42
Interest Coverage 0

Financial Efficiency

Return on equity (ROE) is -0.44% and return on capital (ROIC) is -40.37%.

Return on Equity (ROE) -0.44%
Return on Assets (ROA) -0.32%
Return on Capital (ROIC) -40.37%
Revenue Per Employee 351.01K
Profits Per Employee -889.10K
Employee Count 181
Asset Turnover 0.13
Inventory Turnover 0

Taxes

Income Tax 0
Effective Tax Rate 0

Stock Price Statistics

The stock price has increased by -39.74% in the last 52 weeks. The beta is 1.88, so Fate Therapeutics 's price volatility has been higher than the market average.

Beta 1.88
52-Week Price Change -39.74%
50-Day Moving Average 2.68
200-Day Moving Average 4.1
Relative Strength Index (RSI) 37.62
Average Volume (20 Days) 2.40M

Income Statement

In the last 12 months, Fate Therapeutics had revenue of $63.53M and earned -$160.93M in profits. Earnings per share was $-1.64.

Revenue 63.53M
Gross Profit -98.16M
Operating Income -190.51M
Net Income -160.93M
EBITDA -172.23M
EBIT -190.51M
Earnings Per Share (EPS) -1.64
Full Income Statement

Balance Sheet

The company has $41.87M in cash and $103.54M in debt, giving a net cash position of -$61.67M.

Cash & Cash Equivalents 41.87M
Total Debt 103.54M
Net Cash -61.67M
Retained Earnings -1.21B
Total Assets 494.97M
Working Capital 272.87M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$132.26M and capital expenditures -$6.15M, giving a free cash flow of -$138.42M.

Operating Cash Flow -132.26M
Capital Expenditures -6.15M
Free Cash Flow -138.42M
FCF Per Share -1.41
Full Cash Flow Statement

Margins

Gross margin is -154.51%, with operating and profit margins of -299.86% and -253.3%.

Gross Margin -154.51%
Operating Margin -299.86%
Pretax Margin -253.3%
Profit Margin -253.3%
EBITDA Margin -271.09%
EBIT Margin -299.86%
FCF Margin -217.86%

Dividends & Yields

FATE does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield -90.11%
FCF Yield -66.78%
Dividend Details

Analyst Forecast

The average price target for FATE is $6, which is 229.7% higher than the current price. The consensus rating is "Hold".

Price Target $6
Price Target Difference 229.7%
Analyst Consensus Hold
Analyst Count 10
Stock Forecasts

Scores

Altman Z-Score -3.41
Piotroski F-Score 2